Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2001

View Archived Issues

Researchers reveal crystal structure of antibody against HIV

Testosterone protects human primary neurons from apoptosis

Hormone replacement therapy has osteoprotective effects in elderly women

Ultracet combination analgesic approved by FDA for acute pain relief

Seattle Genetics initiates phase II trial with SGN-15

Chrysalis reports positive trends from pilot Chrysalin clinical trial for diabetic ulcers

Immunex and Wyeth-Ayerst to commence longitudinal rheumatoid arthritis study

Novogen to initiate clinical trial of oral phenoxodiol in advanced prostate cancer

Ivax announces encouraging phase I results of BNP-166 as treatment of Crohn's disease

Biomira and Merck KGaA to meet with FDA regarding Theratope vaccine

Visudyne approved for additional ocular conditions in the U.S.

Enrollment for study of Zadaxin in hepatitis B in Japan completed

Lilly and Isis establish antisense strategic alliance

Study of Cytran's IM-862 in ovarian cancer begins at Magee-Womens Hospital

Revised Remicade label strengthens warnings about risk of infections

Schering-Plough highlights next-generation farnesyl protein transferase inhibitors at ACS meeting

Patient dosing completed in phase II study of Alista for treatment of FSD

Selective beta3-adrenoceptor agonists designed at Asahi Kasei

Sterix patents novel steroid sulfatase inhibitors

Potent inhibitors of IL-5 gene expression identified at Abbott

Jenapharm reports compounds with affinity for progesterone and/or glucocorticoid receptors

New series of inhibitors of TNF production may be useful as immunosuppressants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...